EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

What happened to shortage-based semaglutide and tirzepatide compounding?

Dose Diligence research deskSection 04 · Page 3 of 17Last updated 17 Nov 2026

The old transition periods have ended; they are not 2026 purchasing windows. FDA’s reconsidered tirzepatide determination is dated December 19, 2024. Its semaglutide injection shortage-resolution determination is dated February 21, 2025. These are national shortage determinations, not assurances that every local pharmacy has every presentation available. Tirzepatide determination; semaglutide determination. (fda.gov)

FDA’s published updates establish the following historical endpoints for the shortage-dependent enforcement-discretion periods:

ProductSection 503ASection 503B
Tirzepatide injectionEnded following the March 5, 2025 preliminary-injunction denialMarch 19, 2025
Semaglutide injectionEnded following the April 24, 2025 preliminary-injunction denialMay 22, 2025

These dates concern specified shortage-dependent violations; they were never an exemption from all quality or other statutory requirements. FDA’s consolidated policy updates. (fda.gov)

Did the appeals restore shortage-era permissions?

The appellate opinions located do not restore them. The Fifth Circuit affirmed the district-court judgments in case 25-10600, concerning tirzepatide, and case 25-10758, concerning semaglutide. Both opinions were initially filed August 27, 2026; the semaglutide opinion was revised September 1. Tirzepatide opinion; semaglutide opinion. (ca5.uscourts.gov)

Buyer action: if a supplier says litigation permits continued supply, request the case number, operative order, protected parties, covered conduct and effective dates. Have counsel verify subsequent docket activity. This review did not independently establish the complete mandate, rehearing or Supreme Court petition history, so it does not describe every possible litigation avenue as exhausted.

Explore the table row by row

A working view of the research

Tirzepatide injection

Section 503A
Ended following the March 5, 2025 preliminary-injunction denial
Section 503B
March 19, 2025

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/media/184606/download?attachment=
  2. fda.gov · Source 2 ↗https://www.fda.gov/media/185526/download?attachment=
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  4. ca5.uscourts.gov · Source 4 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
  5. ca5.uscourts.gov · Source 5 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
Section sources →